Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biogen Idec gains all marketing, distribution and governance rights to TYSABRI in exchange for an upfront payment of $3.25Bn plus tiered contingent payments based on future TYSABRI worldwide sales
Terminates TYSABRI collaboration agreement and eliminate... Biopharmaceuticals, Neurology, AcquisitionsBiogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Marketing | Mergers and Aquisitions | Multiple Sclerosis | Neurology | Pharmaceuticals | Tysabri